Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 23, 2018 08:00 ET | Source: MyoKardia, Inc.

New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation

HCM Patients at Greater Risks of Atrial Fibrillation, Heart Failure and Increased Mortality Younger Age of Diagnosis and Genetic Status Associated with Higher Rates of Long-term Complications and...
August 08, 2018 16:02 ET | Source: MyoKardia, Inc.

MyoKardia Reports Second Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
August 07, 2018 16:01 ET | Source: MyoKardia, Inc.

MyoKardia to Present at the 2018 Wedbush Pacgrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
August 01, 2018 16:30 ET | Source: MyoKardia, Inc.

MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
June 26, 2018 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
May 22, 2018 20:05 ET | Source: MyoKardia, Inc.

MyoKardia Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
May 21, 2018 16:01 ET | Source: MyoKardia, Inc.

MyoKardia Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 21, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
May 21, 2018 07:30 ET | Source: MyoKardia, Inc.

MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO2 and NYHA Classification Improvements Expected to Initiate in Second...
May 10, 2018 16:30 ET | Source: MyoKardia, Inc.

MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
May 10, 2018 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right